Superstring Capital Management LP has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $84.5 Billion distributed in 36 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Cogent Biosciences, Inc. with a value of $6.91B, Verona Pharma PLC with a value of $6.52B, Neurocrine Biosciences Inc with a value of $5.1B, Terns Pharmaceuticals, Inc. with a value of $4.8B, and Ultragenyx Pharmaceutical Inc. with a value of $4.74B.

Examining the 13F form we can see an increase of $408M in the current position value, from $84B to 84.5B.

Superstring Capital Management LP is based out at New York, NY

Below you can find more details about Superstring Capital Management LP portfolio as well as his latest detailed transactions.

Portfolio value $84.5 Billion
Healthcare: $72.4 Billion

Stock Holdings Table Market Cap. of $300 Millions to $2 Billions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 36
  • Current Value $84.5 Billion
  • Prior Value $84 Billion
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 13 stocks
  • Additional Purchases 9 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 9 stocks
Track This Portfolio

Track Superstring Capital Management LP Portfolio

Follow Superstring Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Superstring Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Superstring Capital Management LP with notifications on news.